Oral semaglutide was approved by the FDA in December 2025 as a once-daily pill (25 mg), intended to limit excess body weight ...
The MarketWatch News Department was not involved in the creation of this content. MELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a clinical and ...
VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new global benchmark A potential ...
FeSSIF pH of 5, bile salt; 15 mM of bile salt and 3.75 mM of lecithin FaSSIF-V2 pH of 6.5; 3 mM of bile salt and 0.2 mM of lecithin [32–36] FeSSIF-V2 pH 5.8; 10 mM of bile salt; 2 mM of lecithin and ...
MELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (GELS) (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today ...
VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback